MOD-4023 Study in Healthy Male Volunteers

NCT01060722 | Completed Phase 1

• 1 other identifier: CP-4-001
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to examine the safety, tolerability and pharmacokinetics of a long-lasting Human Growth Hormone (MOD-4023) in healthy volunteers after a single subcutaneous injection at escalating doses.

Conditions

Healthy

Keywords

Healthy Male Volunteers

Outcome Measures

Primary Outcomes (2)

• Safety and Tolerability (AE's, vital signs, ECG, laboratory tests, local reaction)

  30 days

• Pharmacokinetics: AUC, Cmax, Tmax, T1/2

  14 days

Secondary Outcomes (1)

• Formation of anti-drug antibodies

  30 days

Study Arms (3)

MOD-4023, dose level 1

EXPERIMENTAL

Drug: MOD-4023 (long lasting hGH); Drug: Placebo

MOD-4023, dose level 2

EXPERIMENTAL

Drug: MOD-4023 (long lasting hGH); Drug: Placebo

MOD-4023, dose level 3

EXPERIMENTAL

Drug: MOD-4023 (long lasting hGH); Drug: Placebo

Interventions

MOD-4023 (long lasting hGH) DRUG

Single subcutaneous dose of MOD-4023

MOD-4023, dose level 1; MOD-4023, dose level 2; MOD-4023, dose level 3

Placebo DRUG

Single subcutaneous dose of placebo material

MOD-4023, dose level 1; MOD-4023, dose level 2; MOD-4023, dose level 3

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male volunteers aged 18-45 (inclusive) years.
• Body Mass Index (BMI) 19 to 30 kg/m2 (inclusive) and weighing at least 55 Kg.
• Non-smoking (by declaration) for a period of at least 6 months prior to screening visit.
• Subjects in generally good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
• Blood pressure and heart rate within normal limits (blood pressure: systolic 90-140mmHg; diastolic 50-90 mmHg, heart rate 40-100 beats per minute).
• Electrocardiogram (ECG) with no clinically significant abnormalities recorded at screening visit (up to 21 days before dosing) and on dosing day (before drug administration): PR interval within 120 and 200 ms, QRS interval \< 120 ms, and QTc interval ≤ 440 ms.
• Negative HIV, hepatitis B or hepatitis C serology tests at screening
• No clinically significant abnormalities in complete blood count (CBC), prothrombin time (PT, INR), activated partial thromboplastin time (aPTT), chemistry lab tests (liver and renal function) and urinalysis at screening.
• No history of alcohol or drug abuse. Negative urine DoA in screening and on admission. Negative breath alcohol on admission.
• Subjects must agree to use medically accepted form of contraception from dosing day to 12 weeks after drug administration.
• Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study and to provide their written informed consent to participate in the study.

You may not qualify if:

• History of significant neurological (including history of seizures or EEG abnormalities), renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety, tension or agitation) or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medication.
• Diabetes.
• Known allergy to any drug.
• Adherence (for whatever reason) to an abnormal diet during the 4 weeks prior to the study, or subjects with recent significant change in body weight.
• Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.
• Subjects who have received any vaccines within 4 weeks prior to study drug administration.
• Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.
• Participation in another clinical trial with drugs within 3 months prior to dosing (calculated from the previous study's last dosing date).
• Subjects with an inability to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function).
• Subjects that have difficulty fasting or consuming the standard meals that will be provided.
• Subjects with any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.
• Subjects who are non-cooperative or unwilling to sign a consent form.

Sponsors & Collaborators

• OPKO Health, Inc.: lead
• Tel-Aviv Sourasky Medical Center: collaborator

Study Sites (1)

Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel

Location

MeSH Terms

Interventions

MOD-4023

Study Officials

• Jacob Atsmon, M.D.

  Tel-Aviv Sourasky Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2010
• First Posted: February 2, 2010
• Study Start: October 1, 2009
• Primary Completion: January 1, 2010
• Study Completion: January 1, 2010
• Last Updated: September 30, 2019

Record last verified: 2019-09

Locations

IL (1)